Heidi Altmann
Overview
Explore the profile of Heidi Altmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Altmann H, Barovic M, Strassburger K, Tschapel M, Jonas S, Poitz D, et al.
Anal Chem
. 2025 Jan;
97(5):2762-2769.
PMID: 39873382
The quality of biological samples used in metabolomics research is significantly influenced by preanalytical factors, such as the timing of centrifugation and freezing. This study aimed to evaluate how preanalytical...
2.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
3.
Schnetzke U, Fischer M, Rollig C, Scherag A, Altmann H, Stolzel F, et al.
Genes Immun
. 2024 Jul;
25(4):317-323.
PMID: 38982248
Infectious events, such as sepsis and invasive fungal disease (IFD), pose significant risks in patients with acute myeloid leukemia (AML). Previous studies, including our own, have suggested a potential role...
4.
Manoharan J, Rana R, Kuenze G, Gupta D, Elwakiel A, Ambreen S, et al.
Immunity
. 2023 Dec;
57(1):68-85.e11.
PMID: 38141610
Tissue factor (TF), which is a member of the cytokine receptor family, promotes coagulation and coagulation-dependent inflammation. TF also exerts protective effects through unknown mechanisms. Here, we showed that TF...
5.
Liebers N, Bruch P, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, et al.
Nat Cancer
. 2023 Oct;
4(12):1648-1659.
PMID: 37783805
Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted...
6.
Frank D, Patnana P, Vorwerk J, Mao L, Gopal L, Jung N, et al.
Blood
. 2023 Sep;
142(25):2175-2191.
PMID: 37756525
Growth factor independence 1 (GFI1) is a DNA-binding transcription factor and a key regulator of hematopoiesis. GFI1-36N is a germ line variant, causing a change of serine (S) to asparagine...
7.
Heidenreich F, Falk B, Baldauf H, Massalski C, Schafer G, Rucker-Braun E, et al.
Blood Adv
. 2023 Jan;
7(13):2994-3004.
PMID: 36689727
Immunogenetic association studies may give rise to new hypotheses on the immune surveillance of cancer. We hypothesized that certain combinations of killer immunoglobulin-like receptor (KIR) and HLA genotypes may enhance...
8.
Stolzel F, Fordham S, Nandana D, Lin W, Blair H, Elstob C, et al.
JCI Insight
. 2022 Dec;
8(2).
PMID: 36480300
Precision medicine can significantly improve outcomes for patients with cancer, but implementation requires comprehensive characterization of tumor cells to identify therapeutically exploitable vulnerabilities. Here, we describe somatic biallelic TET2 mutations...
9.
Fuchs Y, Brunner J, Weigelt M, Schieferdecker A, Morgenstern R, Sturm A, et al.
Biopreserv Biobank
. 2022 Oct;
21(1):106-110.
PMID: 36251308
No abstract available.
10.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau T, Mukhopadhyay R, et al.
J Clin Invest
. 2022 Sep;
132(21).
PMID: 36099049
BackgroundImmune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In the current study, we characterized how acute myeloid...